DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Rapp-Hodgkin syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRapp-Hodgkin syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for rapp-hodgkin syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tumor protein p63 (TP63) — TP63 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7Z7E · 1.8 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Rapp-Hodgkin syndrome is not mentioned in any of the provided abstracts. The abstracts discuss Hodgkin's disease, a lymphoma, which is a different condition entirely. One abstract from 1915 reports two recoveries defined as five years without evidence of the disease, and notes that no permanent cure had been recorded up to that year. A 1977 abstract states that patients surviving the first five years after treatment have a 95% chance of cure. A 1975 abstract describes Hodgkin's disease as potentially one of the most curable cancers with aggressive treatment, but notes that morbidity and mortality remain significant. A 1978 abstract says the disease can now be cured in the majority of newly diagnosed patients with appropriate staging, radiation and chemotherapy.
No data on Rapp-Hodgkin syndrome, its natural history, or any treatment outcomes for it appear in these abstracts. The sample sizes, response rates, and survival figures given apply only to Hodgkin's disease. There is no evidence here that any drug or management strategy has been tested in Rapp-Hodgkin syndrome.
What is still missing is any clinical research, funding, or trial design specific to Rapp-Hodgkin syndrome. Without patient stratification or any study of the condition itself, no conclusions about treatment can be drawn from these documents.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1978 · 22 citations
The Management of Hodgkin's Disease
AbstractTHE results of the treatment of patients with Hodgkin's disease continue to improve. A disease that was considered uniformly fatal only several decades ago now can be cured in the majority of newly diagnosed patients with appropriate staging, radiation and chemotherapy programs. However, the details of the management of these patients continue to evolve. New treatment programs are being proposed and tested often before the full appreciation of the benefits and complications of former programs have been recorded. The problem is even more complicated since Hodgkin's disease is a disorder that includes a wide spectrum of presenting manifestations, prognoses and . . .
Hodgkin's Disease: Multidisciplinary Contributions to the Conquest of a Neoplasm
AbstractIn the 150 years since the first description of Hodgkin's disease, treatment methods have become increasingly sophisticated and effective. We now know that relapses are concentrated within the first five years after treatment. Accordingly, anyone who survives the first five years has a 95% chance of cure. Modern techniques in diagnosis, staging, and combined chemotherapy and irradiation have brought us within sight of total therapeutic conquest of this once inexorably fatal malady.
Abstract<h3>INTRODUCTORY</h3> A combined pathologic, experimental and clinical study of Hodgkin's disease extending over a period of six years is the basis of this communication. The most efficacious methods of treatment will be presented with sufficient data to justify the various therapeutic procedures held to be indicated. Fischer<sup>1</sup>was unable in 1901 to find a record of a single case in which cure was<i>permanent</i>. None has since then been reported in the literature up to the present year. We have been so fortunate as to have seen two recoveries (that is, five years without evidence of the disease) and at present have a small number of patients under observation who are in a very encouraging condition three to six years after beginning treatment. We believe the disease more common than supposed, more protean in its clinical manifestations than is generally accepted, and not of necessity universally fatal. This is
AbstractThe accepted management of Hodgkin's disease has changed markedly in the past two decades. It should be considered a tumor of unifocal origin and potentially one of the most curable cancers, given early diagnosis, careful evaluation, meticulously accurate staging and aggressive, radical treatment. This requires a team effort, is tedious and expensive, and morbidity and mortality remain significant, but the high yield of long remissions and apparent cures justifies this approach to the problem.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
